Lenalidomide's remarkable efficacy in treating hematological malignancies stems from its intricate and multifaceted mechanism of action. Far from being a single-target drug, Lenalidomide operates on several fronts, disrupting cancer cell survival and growth while simultaneously modulating the body's own immune response.

At its core, Lenalidomide is an immunomodulatory drug (IMiD). It influences both the innate and adaptive immune systems. This includes augmenting the cytotoxic activity of Natural Killer (NK) cells and stimulating T-cell activation via the B7-CD28 co-stimulatory pathway. By enhancing immune surveillance and response, Lenalidomide helps the body's defenses target and eliminate cancerous cells. The mechanism of action of lenalidomide in hematological malignancies also involves altering cytokine production, decreasing pro-inflammatory cytokines like TNF-α and IL-6, which are often dysregulated in cancer. This rebalancing of inflammatory signals contributes to its therapeutic effect.

Beyond its immunological impact, Lenalidomide exhibits potent anti-angiogenic properties. Tumors require a robust blood supply to grow and metastasize. Lenalidomide inhibits the formation of new blood vessels by targeting factors like VEGF, thereby starving the tumor of essential nutrients and oxygen. This anti-angiogenesis aspect is crucial for controlling tumor progression.

Furthermore, Lenalidomide has direct anti-tumor effects. It can induce cell cycle arrest and apoptosis (programmed cell death) in cancer cells, irrespective of immune involvement. Studies show it upregulates CDK inhibitors and influences signaling pathways critical for cell proliferation and survival. This dual action—bolstering the immune system and directly attacking cancer cells—makes Lenalidomide a powerful therapeutic agent. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing high-quality Lenalidomide to support critical research and treatment in this area.